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Abstract
Despite decades of research, accurate diagnosis of Parkinson’s disease remains a challenge, and disease-modifying treat-
ments are still lacking. Research into the early (presymptomatic) stages of Parkinson’s disease and the discovery of novel 
biomarkers is of utmost importance to reduce this burden and to come to a more accurate diagnosis at the very onset of the 
disease. Many have speculated that non-motor symptoms could provide a breakthrough in the quest for early biomarkers of 
Parkinson’s disease, including the visual disturbances and retinal abnormalities that are seen in the majority of Parkinson’s 
disease patients. An expanding number of clinical studies have investigated the use of in vivo assessments of retinal structure, 
electrophysiological function, and vision-driven tasks as novel means for identifying patients at risk that need further neuro-
logical examination and for longitudinal follow-up of disease progression in Parkinson’s disease patients. Often, the results 
of these studies have been interpreted in relation to α-synuclein deposits and dopamine deficiency in the retina, mirroring the 
defining pathological features of Parkinson’s disease in the brain. To better understand the visual defects seen in Parkinson’s 
disease patients and to propel the use of retinal changes as biomarkers for Parkinson’s disease, however, more conclusive 
neuropathological evidence for the presence of retinal α-synuclein aggregates, and its relation to the cerebral α-synuclein 
burden, is urgently needed. This review provides a comprehensive and critical overview of the research conducted to unveil 
α-synuclein aggregates in the retina of Parkinson’s disease patients and animal models, and thereby aims to aid the ongo-
ing discussion about the potential use of the retinal changes and/or visual symptoms as biomarkers for Parkinson’s disease.
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Introduction
In 2016, the number of Parkinson’s disease (PD) patients 
was estimated at over 10 million, making PD the second 
most common neurodegenerative disease worldwide [43]. 
Moreover, due to our increasingly ageing society, age-related 
neurodegenerative diseases, such as PD, will become even 
more prevalent [149, 150]. Up until now, PD cannot be 
prevented, slowed or cured, adding to an augmenting soci-
etal burden. The lack of disease-modifying treatments, poor 
success rate of clinical trials, and the shortage of techniques 
for patient screening and early diagnosis highlight the urgent 
need for intensive research to unravel the complex interplay 
of disease mechanisms underlying PD and to better under-
stand the early manifestations of PD [5, 83].
The defining neuropathological hallmarks of PD are the 
progressive loss of dopaminergic neurons in the substantia 
nigra, on one hand, resulting in reduced striatal dopamine 
levels, and the accumulation of proteinaceous cytoplasmic 
inclusions mainly consisting of aggregated alpha-synuclein 
(αSYN), called Lewy bodies, on the other hand [15, 41]. 
Dopaminergic depletion leads to the development of pro-
gressive motor dysfunction [25], of which the cardinal 
symptoms can be summarised in the acronym TRAP, which 
stands for tremor, rigidity, akinesia (or bradykinesia), and 
postural instability [60, 112].
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Importantly, recent clinical, neuropathological, and imag-
ing evidence suggests an earlier initiation of PD pathology, 
before onset of these cardinal motor symptoms [60, 77, 93]. 
This prodromal phase in PD is particularly interesting for the 
development of early stage diagnosis and intervention [77, 
93]. Therefore, over the past years, the importance of early, 
non-motor manifestations of PD is increasingly recognised 
[112]. These include reduced smell, sleep disturbances, 
mood changes, and gastrointestinal deficits that may emerge 
years or even decades before motor symptoms [25, 49, 77, 
107], and could fit in the emerging interest for biological, 
biomarker-based diagnosis. In this recent view, diseases are 
detected by scans and biochemical assays that assess key 
pathological features (e.g., protein aggregates, neurodegen-
eration) even before symptoms set in. In the case of PD, 
this can further be complemented with assessments of early 
non-motor symptoms. By focusing on the presymptomatic 
phases of disease, a time window for early, more adequate 
treatment can be breached and patients at risk may be identi-
fied before irreversible damage has occurred. Importantly, 
biomarkers are essential to identify these preclinical or 
prodromal patients, as well as for monitoring disease pro-
gression and the effect of a disease-modifying treatment. 
This stresses the need for well-validated biomarkers and 
biomarker combinations. Because the retina might provide 
a window to the pathological processes that are ongoing in 
the brain, more research into the retinal manifestations of 
PD is highly needed to explore whether visual tests and/or 
retinal imaging techniques could be used to monitor retinal 
biomarkers.
In recent years, there has been an expansion of stud-
ies investigating the use of in vivo assessments of retinal 
structure, electrophysiological, and visual function as novel 
means for identifying patients at risk that need further neu-
rological examination and for longitudinal follow-up of 
disease progression in PD patients. These have been exten-
sively reviewed elsewhere (e.g., [7, 10, 22, 49, 70, 138, 148]) 
and fall beyond the scope of this review. Often, the results 
of these studies have been related to dopaminergic deple-
tion and αSYN accumulation in the retina. However, the 
neuropathological evidence for the manifestation of these 
defining PD hallmarks in the retina is scarce and incon-
clusive, hampering our understanding of the retinal/visual 
abnormalities seen in PD patients and their validation as 
retinal biomarkers. In summary, there is evidence that retinal 
dopamine deficiency underlies some of the vision problems 
observed in PD patients, which can be temporarily allevi-
ated with L-DOPA [7, 148, 151]. Furthermore, immuno-
histological studies on post-mortem retinas of PD patients 
suggest that pathological αSYN accumulations are present 
in the retina and/or visual system [15, 20, 53, 98], although 
it remains elusive whether the functional deficits and struc-
tural neurodegenerative changes in the retina are related to 
these αSYN deposits. Finally, information on the presence 
of retinal αSYN deposits in animal models is still scarce, 
as PD pathology in these models is mainly studied in the 
brain, while the retina is largely overlooked [34, 93, 113, 
120]. Only in toxin-induced models, retinal PD manifesta-
tions were studied in the retina [56, 93, 141], while in more 
recent viral vector- and αSYN fibril-based studies, this is not 
the case yet [26, 96, 102, 142]. In transgenic rodent models, 
only two papers report on retinal αSYN accumulation in 
two different transgenic mice: one expressing human A53T 
αSYN under the control of the Prnp promoter (TgM83) [78], 
the other expressing fused αSYN::GFP under the PDGFβ 
promoter [113]. In this review, new preliminary data on the 
presence of αSYN and phospho-αSYN in the retina of (Thy-
1)-h[A30P] αSYN mice are provided. However, the direct 
impact of αSYN accumulation on the structure and function 
of the retina remains to be studied.
The aim of this review is to provide a comprehensive 
and critical overview of the research conducted to unveil 
α-synuclein aggregates in the retina of PD patients and ani-
mal models and to outline outstanding questions and future 
challenges. It may thereby aid the ongoing discussion about 
the potential use of visual symptoms and retinal abnormali-
ties as biomarkers for diagnosis and disease monitoring of 
PD and the implementation of the retina as a model organ 
to study PD processes.
The eye as a window to the brain
The strong link between the eye and the brain has led to 
an emerging concept in neurobiological research: “the eye 
as a window to the brain” [34, 75]. Indeed, the retina is an 
integral part of the CNS, displaying striking similarities to 
the other CNS structures in terms of anatomy, response to 
insult, and immunology [75]. This strong interplay between 
the brain and the retina is underscored by the presence of 
retinal manifestations in many neurodegenerative diseases 
or insults, e.g., Alzheimer’s disease, Huntington’s disease, 
multiple sclerosis, and stroke [3, 29, 86, 120, 124].
Furthermore, the retina is the most accessible part of the 
CNS, and the unique properties of the eye in terms of in vivo 
imaging, manipulation, and administration of compounds, 
can be exploited for both fundamental and clinical research 
of CNS diseases [34, 75]. In addition, some retinal manifes-
tations are suggested to be present and/or detectable before 
typical cerebral manifestations [34, 93, 125, 138]. Indeed, 
given that the resolution of current retinal imaging tech-
niques is at least an order of magnitude higher than available 
brain imaging techniques, they might be able to detect more 
subtle changes (i.e., earlier disease stages). The eye thus can 
offer an alternative approach, which can complement brain 
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examinations/research, especially in terms of early diagnosis 
and disease monitoring [77, 93].
Thanks to the accessibility and the transparency of the 
anterior segment of the eye (in contrast to the bony skull 
that covers the brain), an array of technologies allows non-
invasive, high-resolution imaging of the retina, e.g., confocal 
scanning laser ophthalmoscopy (cSLO), optical coherence 
tomography (OCT), adaptive optics, and oximetry [13]. In 
combination with electroretinography (ERG), visual-evoked 
potentials, and visual function tests, these techniques are 
routinely used to detect (early) changes in retinal morphol-
ogy, blood flow, electrophysiology, and visual performance. 
Especially relevant, or most commonly used, to the study of 
PD in the retina, are OCT, cSLO, and ERG. Optical coher-
ence tomography provides structural information on ocular 
tissues with 1-to-10 μm resolution, and enables direct obser-
vation of remodelling of the retinal tissue and morphomet-
ric measurements of retinal layer thickness [6]. A second 
non-invasive, diagnostic imaging technique for the retina is 
confocal scanning laser ophthalmoscopy, which produces 
an en face view of the retina on which changes in the optic 
nerve head, vasculature, and retinal tissue morphology can 
be assessed [147]. In addition, cSLO can be used to detect 
fluorescent signals, an application upon which the ‘Detec-
tion of Apoptosing Retinal Cells’ (DARC) technique for sin-
gle-cell imaging of apoptotic cells is based [14, 44]. Electro-
retinography, finally, together with visual-evoked potentials 
(VEP), has proven very sensitive in revealing alterations in 
the electrical responses of various retinal cell types, thereby 
pinpointing the exact circuitries affected. Pattern electrore-
tinography (PERG), more specifically, uses pattern-reversal 
stimuli to capture retinal ganglion cell activity [46].
Retinal manifestations of Parkinson’s 
disease
Visual symptoms in Parkinson’s disease patients
Almost 80% of PD patients report at least one visual symp-
tom, resulting from either defects in primary vision, such as 
visual acuity [8, 54, 61, 85], spatial contrast sensitivity [19, 
21], and colour vision [52, 114, 122, 130], or deficits in more 
complex visual tasks [8, 9, 11, 49, 110, 135, 148]. One of 
the most prevalent visual dysfunctions among PD patients is 
impaired colour vision, which is reported to manifest several 
years before diagnosis and to correlate with disease progres-
sion (i.e., motor function) [38, 52, 114, 122]. Next, one in 
three PD patients has issues with seeing fine detail due to 
reduced visual acuity and visuospatial processing, a feature 
that is also correlated with motor performance [61, 85]. 
Third, some of the earliest visual abnormalities due to PD, 
together with colour recognition, are poor vision at dim light 
conditions and the disability to perceive small increments 
of light versus dark, which are manifestations of reduced 
contrast sensitivity. Given its progression and correlation 
with disease severity, reduced contrast sensitivity has been 
suggested to be a valuable biomarker for early PD [19, 38, 
49, 52, 109, 114, 134, 138, 146]. Notably, changes in colour 
discrimination and contrast sensitivity have shown a dis-
criminatory power for early diagnosis that outweighs non-
motor symptoms such as hyposmia and sleep disturbance 
[148]. Besides these manifestations in the neuroretina of PD 
patients, other parts of the eye are reported to be affected as 
well, e.g., the pupil and lens, leading to blurred vision due 
to disordered pupil reactivity and cataract, respectively [94].
While visual dysfunctions experienced by PD patients are 
at least in part to be attributed to defects in subcortical and 
cortical areas for visual processing [16, 86], electrophysio-
logical tests, and structural imaging prove that they are (also) 
the result of local retinal pathogenesis. Indeed, several OCT 
studies have demonstrated retinal nerve fibre layer thinning 
in PD patients as compared to age-matched controls [12, 24, 
70, 75, 84]. In addition, studies comparing retinal nerve fibre 
layer thickness in the four retinal quadrants demonstrated 
that the temporal quadrant is most commonly affected. This 
is of particular interest, given that this quadrant is typically 
affected in mitochondrial optic neuropathies [34, 68, 79] 
and that PD has been linked to mitochondrial dysfunction 
[4, 58, 68, 91]. PD patients also display thinning of the inner 
retinal layers: the ganglion cell layer, inner plexiform layer, 
and inner nuclear layer [1, 22, 71, 128, 133]. Together, these 
observations are suggestive of a loss of retinal ganglion cells 
(cfr. retinal nerve fibre layer, ganglion cell layer, and inner 
plexiform layer changes) and a thinning of the dopaminergic 
plexus (cfr. inner plexiform layer and inner nuclear layer 
changes) [19, 32, 88, 139]. These findings are corroborated 
by ERG studies, which have shown significant changes in 
ERG responses in PD patients. On one hand, decreases in the 
amplitude of the photopic b-wave and scotopic oscillatory 
potentials were observed [27, 48, 57, 95], which are diag-
nostic indicators of the functioning of retinal interneurons, 
which comprise, amongst many other cells, dopaminergic 
amacrine cells [10]. Of note, decreased dopamine levels 
have been shown to affect scotopic oscillatory responses 
[95]. On the other hand, a reduced amplitude and delayed 
latency of the P50 component of the PERG were recorded 
[45, 48, 69, 92, 103–105, 121], for which there is also evi-
dence that these can be correlated with disturbed dopamine 
signalling affecting the retinal ganglion cells [10, 120].
Histopathological evidence
In the brain, the defining neuropathological features of PD 
are loss of dopaminergic neurons and accumulation of αSYN 
inclusions, both of which are confirmed post-mortem via 
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histopathological examination. While in vivo evidence from 
OCT and ERG studies points to dopaminergic degeneration 
in the retina as well, only one paper reveals post-mortem 
evidence for a reduction in dopamine levels to support and 
better understand these findings [30, 39, 51]. Nonetheless, 
dopaminergic involvement is underscored by the transient 
improvement in visual function tests and PERG responses 
upon administration of L-DOPA and by post-mortem stud-
ies revealing reduced retinal tyrosine hydroxylase expres-
sion [7, 51, 61, 120]. In addition, a recent study reported 
reduced melanopsin-immunoreactive retinal ganglion cell 
(mRGC) density and complexity of the melanopsin plexus in 
the retina of PD patients. While being involved in circadian 
rhythm, commonly affected in PD, a subset of these mRGCs 
also receives dopaminergic input, and their loss may thus 
be linked to a diminution of retinal dopamine levels (i.e., a 
loss of their main synaptic inputs) [99]. Furthermore, little 
histopathological proof for retinal accumulation of αSYN 
inclusions has been gathered thus far.
Studies on αSYN and phosphorylated αSYN 
in the retina of Parkinson’s disease patients
Between 2014 and 2018, four studies have investigated the 
presence of αSYN or phospho-αSYN in the retina of PD 
patients, in a total of 27 PD patients and 24 age-matched 
controls [15, 20, 53, 98]. In the years before, endogenous 
αSYN had already been described for the healthy retina 
[72, 82]. The methodology and primary findings of these 
studies are summarised in Table 1 and Fig. 1. First of all, 
in healthy subjects, two independent studies described the 
presence of endogenous αSYN in the inner nuclear layer 
and in the ganglion cell layer [72, 82]. In addition, the outer 
segments of the photoreceptors in the photoreceptor layer 
and their terminals in the outer plexiform layer were strongly 
immunoreactive for αSYN, and αSYN-positive cell bodies 
and neurites were detected in the inner nuclear layer and 
the inner plexiform layer, respectively [82]. These obser-
vations might be reconciled with αSYN in its monomeric 
form, which is predominantly located in the cytoplasm of 
presynaptic nerve terminals of both dopaminergic and non-
dopaminergic neurons, and of which the physiological func-
tion has been suggested to be related to synaptic plasticity, 
vesicle trafficking, and neurotransmission [41].
In PD retinas, however, additional αSYN was found that 
had accumulated into insoluble aggregates, undergone con-
formational changes, and/or abnormal phosphorylation. 
First, Bodis-Wollner et al. [20] demonstrated a distinct pat-
tern of intense αSYN immunoreactivity in different retinal 
layers: upon immunostaining for native αSYN, 8–10-μm 
globular inclusions were reported in inner nuclear layer 
neurons, αSYN-positive neurites were seen in the inner 
plexiform layer, and both intra- and extracellular αSYN-
positive inclusions were found in the ganglion cell layer. 
Importantly, this immunoreactivity pattern was seen in the 
central and peripheral retina and was consistent for all eight 
PD retinas investigated. Furthermore, morphometric analysis 
of the retina pointed to a thinner inner retina, especially the 
inner nuclear layer. Although the authors suggest that this 
latter change might be due to a loss of dopaminergic cells, 
one should consider that the fraction of dopaminergic cell 
bodies in the inner nuclear layer is limited and, therefore, 
unlikely to account for substantial inner nuclear layer thin-
ning. In fact, there is more evidence pointing to the loss of 
dopaminergic processes in the inner plexiform layer, which 
constitute a large plexus and, therefore, may account for sub-
stantial inner retinal thinning when lost [19, 32, 88, 139].
More evidence for the accumulation of αSYN deposits 
in the retina was gathered by Ortuno-Lizaran et al. [98] and 
Beach et al. [15], who both investigated the presence of 
αSYN phosphorylated at serine-129. These studies inves-
tigated nine PD patients each, and found phospho-αSYN 
immunoreactivity in all nine patients and in seven out of 
nine PD patients, respectively. Immunostaining for phospho-
αSYN was also found in a subset of incidental Lewy body 
disease patients (three of four and one of three, respec-
tively), yet was absent in all control retinas (four and six 
subjects, respectively). Ortuno-Lizaran et al. [98] described 
that phospho-αSYN deposits were present in axonal fibres, 
dendrites, and neuronal perikarya. Although the cell mor-
phology and soma size of the affected neurons varied, dou-
ble stainings confirmed that these cells were all retinal gan-
glion cells, and no inclusions were seen in (dopaminergic) 
amacrine cells [98]. In contrast, Beach et al. did not observe 
any intraneuronal inclusions, except for one case, and con-
cluded that the phospho-αSYN immunopositive fibres seen 
in their study must be centrifugal/retinopetal fibres originat-
ing from the brain or retinal ganglion cell (RGC) axons [15].
Strikingly, both Bodis-Wollner et al. [20] and Ortuno-
Lizaran et al. [98] claimed that the retinal αSYN inclusions 
that they found displayed characteristics reminiscent of clas-
sic Lewy bodies and neurites. According to Bodis-Wollner 
et al., intracytoplasmic αSYN staining in the inner nuclear 
layer and ganglion cell layer was condensed into globular 
inclusions replacing other cell components, while Lewy-
like neurites were observed in the IPL. Ortuno-Lizaran et al. 
performed a phospho-αSYN staining and revealed deposits 
in neuronal perikarya, as well as phospho-αSYN-positive 
neurites resembling Lewy neurites with typical dystrophic 
morphology. Finally, abnormal beading, swollen axonal seg-
ments, and increased tortuosity and swelling of the dendrites 
suggested that the phospho-αSYN-positive neurons found 
in this study were dysfunctional and/or undergoing neuro-
degeneration [20, 98]. Importantly, in the study by Bodis-
Wollner et al., an antibody for total non-modified αSYN was 
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used, while Ortuno-Lizaran et al. used a phospho-αSYN spe-
cific antibody. Given that phospho-αSYN is an indicator of 
increased αSYN aggregation/toxicity and more relevant than 
total or native (unphosphorylated) αSYN to evaluate Lewy 
body pathology (as highlighted in Table 2), caution is thus 
warranted when interpreting the findings of Bodis-Wollner 
et al., and overall, one can assume phospho-αSYN to have a 
higher value as PD biomarker.
Although Ortuno-Lizaran et  al. [98] reported that 
phospho-αSYN accumulation was sparse, with relatively few 
retinal ganglion cells affected, quantification of the number 
of immunopositive retinal ganglion cells in the nasal-infe-
rior quadrant revealed a strong positive correlation between 
Lewy‐type synucleinopathy density in the retina and brain. 
Furthermore, retina Lewy‐type synucleinopathy density 
score correlated with the Unified Parkinson’s disease pathol-
ogy stage. Importantly, retinas from patients with incidental 
Lewy body disease were included in this study, besides cases 
of moderate-to-severe PD [81]. Hereby, this study was the 
first to present evidence that phospho-αSYN accumulates 
in the retina in parallel with the brain, including in the early 
stages preceding development of clinical signs of Parkinson-
ism or dementia.
Notably, Ortuno-Lizaran et al. [98] also looked at native 
αSYN, albeit using a different antibody than Bodis-Wollner 
et al. [20], and found ubiquitous expression in the photore-
ceptor outer segments and the amacrine cells in the inner 
nuclear layer, that was identical in PD patients and healthy 
subjects [98]. Likewise, Ho et  al. [53] reported diffuse 
cytoplasmic staining of native αSYN in the inner nuclear 
layer and ganglion cell layer that was comparable in six PD 
patients and six age-matched controls. Both studies failed 
to find Lewy bodies in the retina of PD patients. On the 
OCT
non-PD PD patients
RNFL
GCL
IPL
INL
OPL
ONL
PL
post mortem (P)ERG
αSYN+ Lewy-like neurites
p-αSYN+ Lewy-like neurites
αSYN inclusions
p-αSYN inclusions
thinning
αSYN
p-αSYN
decrease
TH
#1
#3#2
ba
Fig. 1  Schematic overview of a αSYN expression in healthy retinas 
and b (phospho-)αSYN expression and related pathological processes 
in the retina of PD patients. a Post-mortem examinations on cross 
sections of the retina reveal the presence of αSYN in four retinal lay-
ers in non-PD subjects. b In PD patients, in addition, pathological 
αSYN accumulation is found, which presents as phospho-αSYN and 
Lewy-like inclusions and neurites. Furthermore, decreased dopamine 
levels in the total retina and decreased TH immunoreactivity in the 
IPL are observed. OCT studies report thinning of the inner retina. 
PERG studies show (#1) reduced amplitude and delayed latency of 
the P50 component in PD patients, which are indicators of affected 
retinal ganglion cell (yellow) function. ERG studies demonstrate (#2) 
a decrease in the amplitude of the photopic b-wave, a read-out of 
bipolar cell (pink) malfunction; and (#3) reduced scotopic oscillatory 
potentials, indicating disturbed neuronal activity of the amacrine cells 
(orange). αSYN alpha-synuclein, p-αSYN phosphorylated serine-129 
αSYN, OCT optical coherence tomography, (P)ERG (pattern) electro-
retinography, TH tyrosine hydroxylase, DA dopamine, RNFL retinal 
nerve fibre layer, GCL ganglion cell layer, INL inner nuclear layer, 
IPL inner plexiform layer, ONL outer nuclear layer, OPL outer plexi-
form layer, PL photoreceptor layer
Table 2  Table outlining the basic biochemistry from soluble αSYN to 
aggregates to deposits
Progression of αSYN aggregation in the tissues is accompanied by 
increased phosphorylation of the Serine-129 residue of αSYN and the 
formation of morphologically distinct deposits (the so-called Lewy 
bodies and Lewy neurites). Typically, Lewy bodies are spherical 
intraneuronal cytoplasmic inclusions, characterised by a dense core, 
concentric lamellar bands, and (at least for some types of Lewy bod-
ies) narrow pale halos, and immunoreactivity for αSYN (and other 
aggregation markers, such as p62 and ubiquitin), while Lewy neurites 
appear as αSYN-positive, thread-like dystrophic neurites [129]. Inter-
pretation of immunohistological stainings of αSYN should ideally 
take into account these defining features to describe the pathological 
status of the tissue under investigation
a Of note, whether phosphorylation comes before or mainly after the 
formation of αSYN deposits is still debated [76, 100, 153]
Soluble 
αSYN
αSYN 
aggregates
αSYN 
deposits
Native αSYN + + +
Phosphorylated αSYNa − ± + (+)
Morphological interpretation of 
Lewy body/neurite character-
istics
− − +
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one hand, this reconciles the notion that phospho-αSYN 
is the preferred neuropathological marker of disease (cfr. 
above and Table 2). On the other hand, these contradict-
ing findings point out the shortcomings of the studies that 
are currently available. First of all, due to the difficulty in 
obtaining high-quality post-mortem human retinas, the 
number of patients in each of the studies is relatively low, 
and at this point still does not allow to make extrapolations 
of the prevalence and specificity of retinal αSYN deposits 
to the general population. Second, different αSYN species 
(native versus phosphorylated) have been investigated, being 
indicative of a distinct pathological status; total αSYN anti-
bodies stain both soluble and aggregated forms of αSYN, 
while phosphorylation-specific antibodies identify αSYN 
species with increased aggregation propensity and toxicity 
(Table 2). Third, different methodologies might underlie the 
different results. These include differences in and/or lack 
of immunohistochemical methods, comprehensive retinal 
tissue processing and wholemount techniques, and quality 
of available αSYN antibodies [31]. In particular, for αSYN 
immunostainings, the time between death of the subject and 
fixation of the tissue, the fixation time, and antigen retrieval 
method have been shown to lead to variability in staining 
results [2, 66, 106]. Furthermore, whereas most antibodies 
against αSYN are directed against an epitope at the C termi-
nus of αSYN (Table 1) [37], the exact amino acid sequences 
differ, and this may (co-)account for variability in the stain-
ing results. Finally, it has been suggested that the sparse reti-
nal αSYN inclusions can easily be missed when evaluating a 
limited number of retinal sections; thus, retinal wholemount 
preparations are preferred over sections [97, 98].
Figure 2 shows a series of unpublished immunostain-
ings for total, unmodified αSYN and phospho-αSYN on 
retinal sections and flatmount preparations of PD subjects 
Fig. 2  Immunostainings for 
total and phosphorylated 
αSYN on retinal sections and 
flatmounts of a PD patient and 
healthy control subject. a, b 
Immunostaining for total αSYN 
on retinal sections of a control 
and b PD subjects reveals 
αSYN expression in the photo-
receptor outer segments, in cell 
bodies of the INL and GCL, 
and in their stratifications in the 
IPL, not displaying differences 
in the staining pattern between 
both groups. c Phospho-αSYN 
staining in a PD retinal section 
shows expression in axons 
(arrowheads) and cell body in 
the GCL (arrow). d–g Phospho-
αSYN in retinal PD flatmounts 
is found in d ganglion cells 
(cell body and dendrites), e 
in axons in the NFL, and in f 
Lewy neurites (arrowheads) and 
f, g Lewy bodies located in the 
GCL. Scale bar 50 µm. NFL 
nerve fibre layer, GCL ganglion 
cell layer, INL inner nuclear 
layer, IPL inner plexiform 
layer, ONL outer nuclear layer, 
OPL outer plexiform layer, 
ONL outer nuclear layer, αSYN 
alpha-synuclein, p-αSYN αSYN 
phosphorylated at serine-129
GCL
IPL
OPL
INL
ONL
GCL
IPL
OPL
INL
ONL
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OPL
INL
ONL
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NFL NFL
ba
dc
fe g
Control PD
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and healthy controls, according to the methods published 
by Ortuno-Lizaran et al. [98]. As described in their recent 
manuscript, phospho-αSYN staining was found in axonal 
fibres, dendrites, and neuronal perikarya of PD retinas only, 
and phospho-αSYN-positive neurites displayed features of 
a dystrophic morphology (Fig. 2c–g). Importantly, immu-
nostainings for native αSYN revealed identical staining pat-
terns in PD and control retinas (Fig. 2a, b), again corroborat-
ing phospho-αSYN but not total/native αSYN as a potential 
biomarker of PD.
In conclusion, half a dozen immunohistological studies 
have investigated the presence of native and phosphoryl-
ated αSYN in the retina. Their major findings are summa-
rised in Fig. 1. They showed that native αSYN in healthy 
control retinas is most abundant in the photoreceptor outer 
segments, in the outer plexiform layer and in neurons and 
their processes in the inner nuclear layer and inner plexiform 
layer. Results from studies looking at PD retinas are some-
what contradictory, yet overall, they do provide evidence 
for the presence of phospho-αSYN-positive cell bodies and 
neurites in the retinal nerve fibre layer, ganglion cell layer, 
and inner plexiform layer. Several of these studies suggest 
that ganglion cells and (dopaminergic) amacrine cells are 
preferentially affected and that this also corresponds to the 
structural and functional changes that have been reported 
in OCT and ERG studies in PD patients [12, 24, 75, 84]. 
It currently remains unclear, however, how the significant 
structural effects can be reconciled with the relatively low 
numbers of dopaminergic amacrine cells in the retina, yet 
very large dopaminergic plexus, and detailed histological 
studies are warranted to univocally demonstrate the involve-
ment of dopaminergic retinal neurons. Finally, earlier this 
year, Ortuno-Lizaran et al. were the first to provide evidence 
that PD progression in the retina and brain is related and that 
retinal phospho-αSYN inclusions may provide information 
about the disease severity in the brain, already in an early 
presymptomatic stage of PD.
The retina in animal models of Parkinson’s 
disease
The observation that retinal αSYN inclusions can be found 
in PD patients raises many new research questions, includ-
ing whether the mechanistic pathway that leads to retinal 
neurodegeneration and/or -dysfunction is related to αSYN 
accumulation, whether retinal αSYN burden can be used as 
a biomarker for improved diagnosis and disease monitoring, 
how these αSYN inclusions can be visualised non-invasively 
in vivo, etc. Further research into αSYN pathology in the 
retina is thus highly needed, not only in PD patients, but also 
in animal models. As in the patient studies, PD research in 
animal models has been mainly focused on the brain, while 
the retina, and more specifically αSYN in the retina, is 
understudied [34, 120]. Nevertheless, several animal mod-
els are available to study PD, ranging from toxin-induced 
models to transgenic models to viral vector-based models, 
each having their specific strengths and limitations [18, 33, 
59, 141], and thereby unique characteristics to address par-
ticular research questions [40, 47]. In the following section, 
we give an overview of the retinal manifestations that have 
been studied in these different animal models.
Toxin‑induced models
Classical neurotoxin-induced rodent and primate models 
of PD make use of systemic administration or intracranial 
injection of drugs, such as 6-hydroxydopamine, 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone or 
paraquat. Treated animals typically display dopaminergic 
neurodegeneration in the substantia nigra and striatal dopa-
mine depletion, with subsequent motor syndrome [59, 141]. 
Although increased αSYN immunoreactivity was detected in 
the brain of 6-hydroxydopamine lesioned rats [55, 154, 158] 
and in MPTP mouse [156] and macaque monkey [50] mod-
els, actual Lewy bodies have not been detected [59, 141]. 
Only in the rat rotenone model, Lewy body-like inclusions 
are formed in the cytoplasm of nigral neurons [17, 59, 127].
The failure of most toxin-induced models to display Lewy 
body pathology in the brain logically results in a limited 
number of studies looking at αSYN inclusions in the retina. 
For the rat rotenone model, one study by Normando et al. 
[93] revealed an increase in diffuse αSYN immunostaining 
in all retinal layers of treated rats, 60 days post rotenone 
administration [93]. Furthermore, in vivo OCT and DARC 
measurements showed that retinal neurodegeneration peaks 
at day 20 post rotenone administration in this model, while 
histological evidence for dopaminergic degeneration in 
the substantia nigra and striatum becomes only visible at 
day 60. As such, this was the first paper to report that sig-
nificant alterations in the retina occur before the classical 
PD symptoms in the brain and to claim that the retina can 
be used as a potential biomarker tissue for early diagno-
sis [93]. Inner retinal layer thinning was also confirmed in 
other studies using the rodent rotenone model, in addition 
to decreased expression of dopaminergic cell markers and 
photoreceptor loss [42, 119, 155, 157]. While little atten-
tion has been devoted to retinal αSYN deposits, retinal 
function and structure have been studied more intensively 
in toxin-induced models, and has unveiled the importance of 
dopaminergic signalling in the retina. In 6-OHDA models, 
diminished dopamine levels were reported in rats [87], as 
well as abnormal PERG responses of the retinal ganglion 
cells in monkeys [23]. In MPTP-injected mice, rabbits, and 
monkeys, reductions in the number of tyrosine hydroxylase-
immunopositive amacrine cells and in retinal dopamine 
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levels were found [32, 56, 136, 152], leading to abnormal 
VEP and ERG responses and a decline in visual acuity and 
contrast sensitivity [23, 56]. In the MPTP monkey model, 
also retinal nerve fibre layer thinning, a decreased macula 
volume and foveal thickness were shown using OCT [125], 
similar to what is seen in PD patients. Finally, the potential 
of the retina as a site of novel biomarkers was underscored 
by a study applying cSLO imaging of retinal astrocytes 
in transgenic GFAP–GFP reporter mice that had received 
MPTP. Besides an increase in reactive gliosis that coincided 
with dopaminergic degeneration, this study also showed that 
this technology can be used to evaluate anti-inflammatory 
PD drugs [67].
Transgenic models
Besides toxin-induced models, genetic rodent models of PD 
carrying a wide array of mutations that have been linked 
to PD are used, including transgenic models with SNCA 
or LRRK2 mutations, and knockout mice of Smad-3, Par-
kin, PINK-1, and DJ-1 [33, 47]. Transgenic αSYN animals 
often develop proteinaceous inclusions in the brain, but lack 
robust neurodegeneration [33, 47, 141]. Even though a mul-
titude of transgenic mice and rats carrying SNCA (αSYN) 
gene constructs has been created [18, 41, 59, 141], informa-
tion on αSYN expression in the retina of these rodents is 
limited. In a recent publication of Mammadova et al. (2018), 
αSYN was shown to accumulate in the inner and outer retina 
of 8-month-old TgM83 transgenic mice, expressing A53T 
human αSYN under the control of the Prnp promoter, while 
phospho-αSYN was only present in the outer nuclear layer. 
In addition, transgenic mice of 8 months of age exhibited 
increased microglial activation, followed by increased GFAP 
immunoreactivity at later ages. No differences in retinal 
tyrosine hydroxylase immunoreactivity were observed [78]. 
Visual function abnormalities have not yet been character-
ised in this model.
Given the lack of well-characterised mouse models to 
study the retinal manifestations of PD, we performed αSYN 
and phospho-αSYN immunohistochemistry in the (Thy-1)-
h[A30P]αSYN transgenic mouse eye. While the cerebral 
phenotype of these mice is thoroughly studied, the retinal 
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Fig. 3  Immunostainings for total and phosphorylated αSYN on reti-
nal sections and flatmounts of the Thy1-h[A30P]αSYN transgenic PD 
mouse model, at 15 months of age. a, b Immunostainings of retinal 
cross sections with an antibody recognising both human and mouse 
αSYN (clone 42, BD Transduction Laboratories) reveal a endogenous 
mouse αSYN expression in sparse cell bodies in the GCL and INL, 
and in the IPL of a wild-type mouse and b increased αSYN levels in 
Thy1-h[A30P]αSYN mice (versus wild-type) due to a combination of 
endogenous mouse αSYN and transgenic human αSYN expression. c 
Representative microscopic image of a retinal section immunostained 
for total (unmodified) human αSYN (clone Syn211, Millipore) shows 
expression in somata in the GCL and INL, and neurites/synapses in 
the IPL. d Phospho-αSYN immunostaining (clone 11A5, Elan Phar-
maceuticals) on a retinal cross section reveals phospho-αSYN in cell 
bodies in the GCL and INL (arrow heads), in neurites/synapses in 
the IPL, and in ganglion cell axons (on top of the GCL). e, f Con-
focal images of a retinal flatmount at different focus planes along 
the z-axis, showing phospho-αSYN expression in e interneurons 
in the INL, f ganglion cells and displaced amacrine cells, ganglion 
cell axons (*), and dendrites (arrow) in the GCL. Of note, no human 
(transgenic) αSYN or phospho-αSYN is found in the wild types (data 
not shown). Scale bar 50  µm. GCL ganglion cell layer, INL inner 
nuclear layer, IPL inner plexiform layer, ONL outer nuclear layer, 
OPL outer plexiform layer, PL photoreceptor layer, αSYN alpha-synu-
clein, hαSYN human alpha-synuclein, p-αSYN αSYN phosphorylated 
at serine-129
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phenotype is not yet touched upon. First, endogenous mouse 
αSYN expression (clone 42, BD Transduction Laboratories) 
was observed in sparse cell bodies in the ganglion cell layer 
and inner nuclear layer and in the inner plexiform layer of 
wild-type mice (Fig. 3a). Analysis of immunostainings for 
human native αSYN (clone Syn211, Millipore) and phos-
pho-Ser-129 αSYN (clone 11A5, Elan Pharmaceuticals) 
revealed expression of the αSYN transgene in the inner 
retinal layers of (Thy-1)-h[A30P]αSYN mice, of which a 
proportion was phosphorylated (Fig. 3c–f). More in detail, 
prominent neuronal αSYN expression was observed in the 
ganglion cell layer, where the ganglion cells and displaced 
amacrine cells reside, as well as in their neurites in the reti-
nal nerve fibre layer and inner plexiform layer. Moreover, 
dispersed cell bodies in the inner nuclear layer were stained, 
which, based on their morphology and location at the border 
of the inner plexiform and nuclear layers, are presumed to 
be amacrine cells (Fig. 3c). Whether this constitutes a sub-
population of dopaminergic amacrine cells remains to be 
investigated. Phospho-αSYN immunoreactivity was found in 
cell bodies in the ganglion cell layer and in the inner nuclear 
layer, bordering the inner plexiform layer; and in neurites in 
the inner plexiform layer and nerve fibre layer (Fig. 3d–f). 
Notably, these distribution patterns are strikingly similar to 
the ones observed after αSYN and phospho-αSYN immu-
nostainings in human PD retinas (Fig. 2) (Table 1).
In addition, a retinal imaging study in mice overexpress-
ing the αSYN-eGFP fusion protein under the control of the 
PDGFβ promoter revealed an age-dependent increasing 
accumulation of αSYN-GFP in the retinal ganglion cells 
[113]. As such, this study presents a proof-of-concept for 
longitudinal in vivo imaging of the retina to monitor αSYN 
accumulation over time, and thus to evaluate potential ther-
apies [113]. This further supports the possibility of using 
the eye for early diagnosis and follow-up of PD progression 
by monitoring αSYN accumulation in the retina, given that 
non-invasive imaging techniques for αSYN deposits become 
available (cfr. below) [98, 113].
Viral vector‑ and αSYN pre‑formed fibril‑based 
models
Animal models of diseases are inherently linked to their 
advantages and disadvantages, e.g., many of the transgenic 
models do not display dopaminergic degeneration and/or 
an L-DOPA responsive motor phenotype. In a counter reac-
tion to limitations of the latter models, the use of αSYN-
expressing viral vectors and/or inoculation of αSYN-pre-
formed fibrils to induce local pathology is rising [123].
Local viral vector-mediated overexpression of αSYN 
in the mouse and rat substantia nigra induces progressive 
dopaminergic neurodegeneration, αSYN aggregate forma-
tion and motor impairment within a time span of 12 weeks 
[96, 102, 140]. Alternatively, in the inducible pre-formed 
αSYN fibril model, pre-formed fibrils, mimicking aggre-
gated forms of αSYN found in Lewy bodies [26, 101, 108, 
142], are injected into the striatum, substantia nigra, or other 
brain areas, inducing robust Lewy body and Lewy neurite 
formation, leading to loss of tyrosine hydroxylase-positive 
neurons and motor symptoms [108, 142, 143]. Importantly, 
this novel approach has been pivotal in the research into the 
prion-like behaviour of αSYN, and αSYN oligomers/fibrils 
have been shown to seed αSYN aggregation and spreading to 
more distant brain regions [36, 116]. Furthermore, a combi-
natorial approach using injection of fibrillary αSYN species 
in addition to viral vector injections can be used to speed 
up the pathological process and induce robust Lewy-like 
synucleinopathy, consistent neuroinflammation, progres-
sive dopaminergic cell loss, and motor dysfunction [102, 
137]. The viral vector-based models and in particular the 
pre-formed fibril models are quite novel, and therefore, it 
is not surprising that none of the papers that reported on 
these models included any investigation of the retina [96, 
102, 108, 137, 142, 143]. However, the retina and the vis-
ual system should not be overlooked, especially since they 
constitute an ideal model system to study αSYN seeding/
spreading. This was very recently shown in a study by Mam-
madova et al., in which retinal pathology in TgM83 mice 
was shown to be accelerated upon cerebral inoculation with 
brain homogenate from clinically ill transgenic mice. More 
in detail, compared to non-inoculated mice, the retinas of 
inoculated mice had accelerated and increased phospho-
αSYN accumulation and microglia activation [78]. Another 
illustration of this concept comes from the field of prion dis-
ease research, where it was shown that mice inoculated with 
brain homogenate of a Creutzfeldt–Jakob disease patient dis-
played spreading of prion disease-related lesions along the 
visual pathway [74, 115].
Future perspectives
Reconciling the recent advances in our understanding of 
PD, including our increased knowledge on the underlying 
pathological mechanisms and the non-motor aspect of PD, 
new diagnostic criteria for PD have been defined by the 
International Parkinson Disease and Movement Disorders 
Society in 2017. Noteworthy is that the probability that any 
individual will develop PD (i.e., the criteria for prodromal 
PD) is calculated based on a weighted calculation of PD 
predictors. “These criteria represent only a first step in the 
correct description of early stages of PD, and will require 
constant updating as more information becomes available” 
[80, 111]. In this respect, the eye can be a window to the 
brain and the use of measures of visual function, retinal elec-
trophysiology, neurodegeneration, and αSYN deposition, as 
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PD biomarkers or criteria for prodromal PD are currently 
under intense investigation [138]. While the specificity and 
predictive value of OCT and ERG changes in PD patients 
are still under debate, due to overlap with normal ageing and 
other neurological and ophthalmological diseases, the pres-
ence of αSYN deposits in the retina may have high potential 
for early diagnosis of PD.
Two major challenges, however, still need to be tackled 
before in vivo, non-invasive imaging of retinal αSYN inclu-
sions can be brought into practice. First, there remains a 
need for further studies confirming the presence of phospho-
αSYN in the retina of PD patients and the timing of their 
occurrence in the retina relative to the brain. The limited 
number of neuropathological studies available does not 
allow to draw any final conclusions about the prevalence 
and specificity of retinal αSYN inclusions in PD, due to 
the low numbers of patients and differences in study proto-
cols. In addition, future research should include studies with 
patients in different stages of PD, with different subtypes of 
PD, as well as age-matched controls, to assess the potential 
of retinal αSYN burden for monitoring and prediction of 
disease progression, and to evaluate to what extent it can 
differentiate between different α-synucleinopathies and nor-
mal ageing. Importantly, these trials should also concentrate 
on correlating retinal αSYN burden with ante mortem gold 
standard measures for PD diagnosis.
Second, an outstanding question is how to visualise reti-
nal αSYN inclusions in living subjects. In this respect, the 
Alzheimer’s research field is already one step ahead. Albeit 
the neuropathological evidence for the presence of amyloid 
β plaques in the Alzheimer’s disease retina is as limited and 
controversial as for PD [97], several approaches for non-
invasive, high-resolution visualisation of retinal amyloid β 
have already been developed [64, 132]. First, in vivo confo-
cal scanning laser ophthalmoscopy imaging following sys-
temic administration of curcumin, a fluorochrome that is 
safe to use by humans and labels amyloidogenic proteins, 
has shown promising results in Alzheimer’s disease patients, 
with a retinal amyloid β index that correlated well with cer-
ebral amyloid β plaques [62, 63, 65, 126]. A second devel-
opment is the use of BluePeak autofluorescence imaging 
that reveals metabolic stress in the retina using lipofuscin as 
an indicator, and thereby points to inclusion bodies. Inclu-
sions were found in individuals with significant neocortical 
amyloid burden, but not in individuals without substantial 
amyloid aggregation in their brain [132]. Finally, hyperspec-
tral imaging has been put forward as a promising approach 
for label-free amyloid imaging, potentially with a higher 
specificity than the two aforementioned techniques. This 
technique has been shown to detect a decrease in spectral 
reflectance at wavelengths between 460 and 570 nm that is 
indicative of increased Rayleigh scattering due to the pres-
ence of amyloid β. Comparing these spectra to a database 
with amyloid aggregates spectra, it is shown that hyperspec-
tral imaging can accurately visualise retinal amyloid aggre-
gates ex vivo in retinas of patients and in vivo in rodents 
[89, 90]. These three approaches are still in various stages 
of (pre-)clinical development and validation, yet may lead 
to a practical approach for large-scale Alzheimer’s diagnosis 
and monitoring [64, 89, 132].
Similar technologies are needed in the PD research field, 
to visualise retinal αSYN and/or phospho-αSYN and/or 
Lewy bodies in vivo. A recent advance in the PD imag-
ing field is the development of bimolecular fluorescence 
complementation of αSYN, in which overexpression and 
oligomerisation of αSYN are detected in the brain via con-
jugated fluorescence. However, this experimental technology 
has not yet been translated to the retina, and is still very far 
from clinical development [28, 118]. Alternatively, with a 
specificity for amyloidogenic proteins rather than exclusively 
amyloid β, curcumin has been shown to bind to oligomeric 
αSYN species as well. In addition, the amount of curcumin 
binding is positively correlated with the extent of αSYN 
oligomerisation [131]. Together, this suggests that it may 
be an interesting candidate for in vivo labelling of patho-
genic αSYN in the retina, in analogy with its use for amy-
loid labelling in the Alzheimer’s retina [64, 131]. Alterna-
tively, the Anle138b compound may be used to detect αSYN 
aggregation. Animal studies have shown that, upon systemic 
administration, Anle138b binds aggregate-specific αSYN 
sequences, thereby reducing protein aggregation and con-
ferring neuroprotection [73, 144, 145]. Remarkably, upon 
binding of oligomers, Anle138b shows a strong increase 
in fluorescence intensity around 335 nm. Although there 
might be some concerns about the specificity of Anle138b 
for αSYN, this suggests that it could be used in combination 
with confocal scanning laser ophthalmoscopy to visualise 
retinal αSYN deposits [35, 117, 145]. Finally, although not 
yet explored in any study, the theory of hyperspectral imag-
ing could also be applied to αSYN, given that it also reveals 
a specific spectral signature as is the case for amyloid β.
In summary, besides the urgency for additional studies 
gathering more conclusive evidence for the manifestation 
of retinal deposits in the PD retina, there is also need for 
novel imaging techniques to visualise and quantify retinal 
αSYN burden. In the latter quest, animal models of PD will 
be pivotal, and therefore, there is also a demand for well-
characterised models to study retinal alternations in PD. 
Alternatively, given the opportunities of the eye as a research 
model organ, studies focusing on the retina in this mouse 
line might help to unravel the complex interplay of disease 
mechanisms underlying PD.
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Conclusion
In the search for improved methods for diagnosis and dis-
ease monitoring, PD experts have high expectations of novel 
approaches integrating multiple biomarkers and employing 
novel technologies to increase diagnostic yield. Compelling 
evidence for neuropathological, structural, and electrophysi-
ological alterations in the PD retina has led to the suggestion 
that retinal biomarkers could fit in this approach. One of 
the most promising research tracks in this field is the mani-
festation of phospho-αSYN inclusions in the PD retina. To 
further propel research into the use of retinal αSYN burden 
as a diagnostic biomarker, however, a more solid base of 
evidence for the presence of retinal αSYN deposits in PD is 
urgently needed. Together with technological investments in 
the development of non-invasive, high-resolution, preferably 
label-free, αSYN-imaging techniques, this would allow to 
finally assess the potential of the retina as a site to monitor 
extracerebral αSYN. Notably, to tackle these challenges, pre-
clinical studies in animal models of PD seem indispensable, 
and therefore, animal research looking at retinal manifesta-
tions of PD should not lag behind.
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